Signal Peptide Database - Viruses

 Entry Details
ID   4842
Source Database   UniProtKB/Swiss-Prot
UniProtKB/Swiss-Prot Accession Number   P12651    (Created: 1989-10-01 Updated: 2008-11-25)
UniProtKB/Swiss-Prot Entry Name   SPIKE_IBVM
Protein Name   Spike glycoprotein
Gene   S
Organism Scientific   Avian infectious bronchitis virus (strain M41)
Organism Common   IBV
Lineage   Viruses
  ssRNA positive-strand viruses, no DNA stage
    Nidovirales
      Coronaviridae
        Coronavirus
          Coronavirus group 3
Protein Length [aa]   1162
Protein Mass [Da]   128078
Features  
TypeDescriptionStatusStartEnd
signal peptide      potential   1   18
chain   Spike glycoprotein      19   1162
chain   Spike protein S1   potential   19   537
chain   Spike protein S2   potential   538   1162
transmembrane region      potential   1096   1116
topological domain   Extracellular   potential   19   1095
topological domain   Cytoplasmic   potential   1117   1162
glycosylation site   N-linked (GlcNAc...)   potential   51   51
glycosylation site   N-linked (GlcNAc...)   potential   77   77
glycosylation site   N-linked (GlcNAc...)   potential   103   103
glycosylation site   N-linked (GlcNAc...)   potential   144   144
glycosylation site   N-linked (GlcNAc...)   potential   163   163
glycosylation site   N-linked (GlcNAc...)   potential   178   178
glycosylation site   N-linked (GlcNAc...)   potential   212   212
glycosylation site   N-linked (GlcNAc...)   potential   237   237
glycosylation site   N-linked (GlcNAc...)   potential   247   247
glycosylation site   N-linked (GlcNAc...)   potential   264   264
glycosylation site   N-linked (GlcNAc...)   potential   271   271
glycosylation site   N-linked (GlcNAc...)   potential   276   276
glycosylation site   N-linked (GlcNAc...)   potential   306   306
glycosylation site   N-linked (GlcNAc...)   potential   425   425
glycosylation site   N-linked (GlcNAc...)   potential   447   447
glycosylation site   N-linked (GlcNAc...)   potential   513   513
glycosylation site   N-linked (GlcNAc...)   potential   530   530
glycosylation site   N-linked (GlcNAc...)   potential   579   579
glycosylation site   N-linked (GlcNAc...)   potential   591   591
glycosylation site   N-linked (GlcNAc...)   potential   669   669
glycosylation site   N-linked (GlcNAc...)   potential   676   676
glycosylation site   N-linked (GlcNAc...)   potential   714   714
glycosylation site   N-linked (GlcNAc...)   potential   947   947
glycosylation site   N-linked (GlcNAc...)   potential   960   960
glycosylation site   N-linked (GlcNAc...)   potential   979   979
glycosylation site   N-linked (GlcNAc...)   potential   1014   1014
glycosylation site   N-linked (GlcNAc...)   potential   1038   1038
glycosylation site   N-linked (GlcNAc...)   potential   1051   1051
glycosylation site   N-linked (GlcNAc...)   potential   1074   1074
sequence variant         0   0
sequence variant         0   0
sequence variant         0   0
sequence variant         0   0
sequence variant         0   0
site   Cleavage; by host   potential   537   538
compositionally biased region   Cys-rich      1120   1137
short sequence motif   Di-lysine motif   by similarity   1159   1162
coiled-coil region      potential   822   866
coiled-coil region      potential   1055   1083
SP Length   18
 ----+----1----+----2----+----3----+----4----+----5
Signal Peptide MLVTPLLLVTLLCVLCSA
Sequence MLVTPLLLVTLLCVLCSAALYDSSSYVYYYQSAFRPPNGWHLHGGAYAVV
NISSESNNAGSSPGCIVGTIHGGRVVNASSIAMTAPSSGMAWSSSQFCTA
HC
NFSDTTVFVTHCYKYDGCPITGMLQKNFLRVSAMKNGQLFYNLTVSVA
KYPTFKSFQCVN
NLTSVYLNGDLVYTSNETTDVTSAGVYFKAGGPITYKV
MRKVKALAYFV
NGTAQDVILCDGSPRGLLACQYNTGNFSDGFYPFINSSL
VKQKFIVYRENSV
NTTFTLHNFTFHNETGANPNPSGVQNILTYQTQTAQS
GYYNF
NFSFLSSFVYKESNFMYGSYHPSCNFRLETINNGLWFNSLSVSIA
YGPLQGGCKQSVFSGRATCCYAYSYGGPSLCKGVYSGELDLNFECGLLVY
VTKSGGSRIQTATEPPVITRHNYN
NITLNTCVDYNIYGRTGQGFITNVTD
SAVSYNYLADAGLAILDTSGSIDIFVVQGEYGLTYYKVNPCEDVNQQFVV
SGGKLVGILTSR
NETGSQLLENQFYIKITNGTRRFRRSITENVANCPYVS
YGKFCIKPDGSIATIVPKQLEQFVAPLL
NVTENVLIPNSFNLTVTDEYIQ
TRMDKVQINCLQYVCGNSLDCRDLFQQYGPVCDNILSVVNSIGQKEDMEL
LNFYSSTKPAGFNTPFLS
NVSTGEFNISLLLTTPSSPRRRSFIEDLLFTS
VESVGLPTDDAYK
NCTAGPLGFLKDLACAREYNGLLVLPPIITAEMQTLY
TSSLVASMAFGGITAAGAIPFATQLQARINHLGITQSLLLKNQEKIAASF
NKAIGRMQEGFRSTSLALQQI
QDVVNKQSAILTETMASLNKNFGAISSVI
QEIYQQLDAIQANAQV
DRLITGRLSSLSVLASAKQAEHIRVSQQRELATQ
KINECVKSQSIRYSFCGNGRHVLTIPQNAPNGIVFIHFSYTPDSFV
NVTA
IVGFCVKPA
NASQYAIVPANGRGIFIQVNGSYYITARDMYMPRAITAGDI
VTLTSCQANYVSV
NKTVITTFVDNDDFDFNDELSKWWNDTKHELPDFDKF
NYTVPILDIDSEIDRIQGVIQGLNDSLIDLEKLSILKTYIKWPWYVWLAI
AFATIIFILILGWVFF
MTGCCGCCCGCFGIMPLMSKCGKKSSYYTTFDND
VVTEQNRP
KKSV
Original MLVTPLLLVTLLCVLCSAALYDSSSYVYYYQSAFRPPNGWHLHGGAYAVV
NISSESNNAGSSPGCIVGTIHGGRVVNASSIAMTAPSSGMAWSSSQFCTA
HCNFSDTTVFVTHCYKYDGCPITGMLQKNFLRVSAMKNGQLFYNLTVSVA
KYPTFKSFQCVNNLTSVYLNGDLVYTSNETTDVTSAGVYFKAGGPITYKV
MRKVKALAYFVNGTAQDVILCDGSPRGLLACQYNTGNFSDGFYPFINSSL
VKQKFIVYRENSVNTTFTLHNFTFHNETGANPNPSGVQNILTYQTQTAQS
GYYNFNFSFLSSFVYKESNFMYGSYHPSCNFRLETINNGLWFNSLSVSIA
YGPLQGGCKQSVFSGRATCCYAYSYGGPSLCKGVYSGELDLNFECGLLVY
VTKSGGSRIQTATEPPVITRHNYNNITLNTCVDYNIYGRTGQGFITNVTD
SAVSYNYLADAGLAILDTSGSIDIFVVQGEYGLTYYKVNPCEDVNQQFVV
SGGKLVGILTSRNETGSQLLENQFYIKITNGTRRFRRSITENVANCPYVS
YGKFCIKPDGSIATIVPKQLEQFVAPLLNVTENVLIPNSFNLTVTDEYIQ
TRMDKVQINCLQYVCGNSLDCRDLFQQYGPVCDNILSVVNSIGQKEDMEL
LNFYSSTKPAGFNTPFLSNVSTGEFNISLLLTTPSSPRRRSFIEDLLFTS
VESVGLPTDDAYKNCTAGPLGFLKDLACAREYNGLLVLPPIITAEMQTLY
TSSLVASMAFGGITAAGAIPFATQLQARINHLGITQSLLLKNQEKIAASF
NKAIGRMQEGFRSTSLALQQIQDVVNKQSAILTETMASLNKNFGAISSVI
QEIYQQLDAIQANAQVDRLITGRLSSLSVLASAKQAEHIRVSQQRELATQ
KINECVKSQSIRYSFCGNGRHVLTIPQNAPNGIVFIHFSYTPDSFVNVTA
IVGFCVKPANASQYAIVPANGRGIFIQVNGSYYITARDMYMPRAITAGDI
VTLTSCQANYVSVNKTVITTFVDNDDFDFNDELSKWWNDTKHELPDFDKF
NYTVPILDIDSEIDRIQGVIQGLNDSLIDLEKLSILKTYIKWPWYVWLAI
AFATIIFILILGWVFFMTGCCGCCCGCFGIMPLMSKCGKKSSYYTTFDND
VVTEQNRPKKSV
 ----+----1----+----2----+----3----+----4----+----5
Hydropathies  
 

© 2007-2017 Dr. Katja Kapp, Kassel & thpr.net e. K., Dresden, Germany, last update 2010-06-11